Accueil   Diary - News   All news Elsalys Biotech acquires a first-in-class antibody with a dual biological mechanism of action

Elsalys Biotech acquires a first-in-class antibody with a dual biological mechanism of action

Elsalys logo_vertical_CMJN

ELSALYS BIOTECH, a biopharmaceutical company that designs and develops "first-in-class" therapeutic antibodies against cancer and inflammatory diseases, today announced the acquisition of the development and marketing rights of the anti-CD160 antibody from the company MABLIFE.

 

 As the anti-CD160 antibody has shown its efficacy in cancer and eye disease animal models, ELSALYS BIOTECH has already initiated the preclinical evaluation of different humanised versions of this antibody in age-related macular degeneration, an eye disease associated with uncontrolled vascular proliferation.

 

 

The result of this study, which should lead to the selection of a first drug candidate, is expected in the first half of 2016.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree